secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001171843-25-005787
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience appoints Stephen DeNelsky to board, effective Sept 5, 2025
-----------------------------------------------------------------------------

- Stephen DeNelsky, Managing Director at Oaktree Capital Management, appointed to Board and Nominating & Governance Committee.
- He has 30 years of healthcare equity research/valuation experience across life sciences, pharma, devices.
- Compensation includes 110,000 RSUs and $91,000 annual cash retainer (total ~$135,000) for non-employee director.
- DeNelsky also serves on board of Visioncare Inc and previously on Integrated Diagnostics and AMICAS.
- No arrangement for his selection as director and no family relationships with other directors/officers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325005787/0001171843-25-005787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325005787/f8k_090925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer